Focus on Crohn's disease

被引:0
|
作者
Klotz, Caroline [1 ]
Dhooge, Marion [1 ,2 ]
Oudjit, Ammar [3 ]
Barret, Maximilien [1 ,2 ]
Beuvon, Frederic [4 ]
Chaussade, Stanislas [1 ,2 ]
Coriat, Romain [1 ,2 ]
Abitbol, Vered [1 ]
机构
[1] Hop Cochin, AP HP, Serv Gastroenterol, F-75674 Paris, France
[2] Univ Paris 05, Fac Med, F-75014 Paris, France
[3] Hop Cochin, AP HP, Serv Radiol, F-75014 Paris, France
[4] Hop Cochin, AP HP, Serv Anatomopathol, F-75014 Paris, France
来源
PRESSE MEDICALE | 2015年 / 44卷 / 04期
关键词
CLINICAL-RESPONSE; INFLIXIMAB; THERAPY; MAINTENANCE; AZATHIOPRINE; ADALIMUMAB; BIOMARKERS; REMISSION; EFFICACY; ANTIBODY;
D O I
10.1016/j.lpm.2014.07.028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Crohn's disease is an inflammatory bowel disease that affects the entire digestive tract, from the mouth to the anus. The inflammatory disease is transmural and may be complicated by abscesses, fistulas, strictures. Budesonide is used as first-line treatment for a first episode of ileitis. Thiopurines and methotrexate are used as immunosuppressive maintenance therapy. Anti-tumour necrosis factors (TNF) alpha therapy is used as induction and maintenance therapy in case of severe flares or corticodependence. Combination of immunosuppressive therapy and anti-TNF-alpha (combotherapy) prevents the appearance of specific anti drug antibodies. Combotherapy is used in case of severe disease. The goal of the treatment is to achieve clinical remission, endoscopic mucosal healing, and to prevent the occurrence of complications such as strictures, fistulas or abscesses. Anoperineal lesions are found in 10% of the patients at diagnosis. Surgical treatment is indicated for severe medical treatment-resistant patients or complications such as symptomatic stenosis, fistula or abscess unresponsive to medical treatment or immediately complicated.
引用
收藏
页码:411 / 417
页数:7
相关论文
共 50 条
  • [41] Predictors of Perianal Fistula Relapse in Crohn's Disease
    Lukin, Dana J.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (06) : 932 - 933
  • [42] Duodenal Crohn's Disease
    Lightner, Amy L.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (03) : 546 - 551
  • [43] Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients
    Aguas, Mariam
    Bastida, Guillermo
    Cerrillo, Elena
    Beltran, Belen
    Iborra, Marisa
    Sanchez-Montes, Cristina
    Munoz, Fernando
    Barrio, Jesus
    Riestra, Sabino
    Nos, Pilar
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (32) : 4391 - 4398
  • [44] Durability of Infliximab Dose Intensification in Crohn's Disease
    Lin, Kirk K.
    Velayos, Fernando
    Fisher, Elena
    Terdiman, Jonathan P.
    DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (04) : 1013 - 1019
  • [45] Methotrexate for induction of remission in refractory Crohn's disease
    McDonald, John W. D.
    Wang, Yongjun
    Tsoulis, David J.
    MacDonald, John K.
    Feagan, Brian G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (08):
  • [46] Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-α Agents
    Kestens, Christine
    van Oijen, Martijn G. H.
    Mulder, Charlotte L. J.
    van Bodegraven, Ad A.
    Dijkstra, Gerard
    de Jong, Dirk
    Ponsioen, Cyriel
    van Tuyl, Bas A. C.
    Siersema, Peter D.
    Fidder, Herma H.
    Oldenburg, Bas
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (07) : 826 - 831
  • [47] Review of local injection of anti-TNF for perianal fistulising Crohn's disease
    Adegbola, Samuel O.
    Sahnan, Kapil
    Tozer, Philip J.
    Phillips, Robin K. S.
    Faiz, Omar D.
    Warusavitarne, Janindra
    Hart, Ailsa
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2017, 32 (11) : 1539 - 1544
  • [48] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [49] Efficiency and safety of one-year anti-TNF-αtreatment in Crohn's disease: a Polish single-centre experience
    Sochal, Marcin
    Krzywdzinska, Monika
    Gabryelska, Agata
    Talar-Wojnarowska, Renata
    Malecka-Panas, Ewa
    GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2020, 15 (02): : 156 - 160
  • [50] Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease
    Mak, Joyce Wing Yan
    Tang, Whitney
    Yip, Terry Cheuk Fung
    Ran, Zhi Hua
    Wei, Shu Chen
    Ahuja, Vineet
    Kumar, Sudheer
    Leung, Wai Keung
    Hilmi, Ida
    Limsrivilai, Julajak
    Aniwan, Satimai
    Lam, Belsy C. Y.
    Chan, Kam Hon
    Ng, Ka Man
    Leung, Chi Man
    Li, Michael K. K.
    Lo, Fu Hang
    Sze, Alex Shun Fung
    Tsang, Steven Woon Choy
    Hui, Aric J.
    Hartono, Juanda Leo
    Ng, Siew C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (11-12) : 1195 - 1203